Back to top
more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$5.52 USD

5.52
1,317,489

+0.03 (0.55%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.43% and 11.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 28th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 2.00% and -3.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.

Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher

Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.

Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick

Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?

Is (AQST) Outperforming Other Medical Stocks This Year?

Aquestive Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aquestive Therapeutics.

All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy

Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.